Literature DB >> 18310076

Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells.

Shujie Zhao1, Sudhakar Ammanamanchi, Michael Brattain, Lin Cao, Amalraj Thangasamy, Jing Wang, James W Freeman.   

Abstract

Transforming growth factorbeta (TGF-beta) signals through Smad-dependent and Smad-independent pathways. However, Smad signaling is altered by allelic deletion or intragenic mutation of the Smad4 gene in more than half of pancreatic ductal adenocarcinomas. We show here that loss of Smad4-dependent signaling leads to aberrant expression of RON, a phosphotyrosine kinase receptor, and that signaling by RON cooperates with Smad4-independent TGF-beta signaling to promote cell motility and invasion. Restoring Smad4 expression in a pancreatic ductal adenocarcinoma cell line that is deficient in Smad4 repressed RON expression. Conversely, small interference RNA knock down of Smad4 or blocking TGF-beta signaling with a TGF-beta type I receptor kinase inhibitor in Smad4-intact cell lines induced RON expression. TGF-beta-induced motility and invasion were inhibited in cells that express Smad4 and that have low levels of RON compared with isogenically matched cells that were deficient in Smad4. Furthermore, knocking down RON expression in Smad4-deficient cells suppressed TGF-beta-mediated motility and invasion. We further determined that Smad4-dependent signaling regulated RON expression at the transcriptional level by real-time reverse transcription PCR and RON promoter luciferase reporter assays. Functional inactivation by site-directed mutations of two Smad binding sites on the RON promoter inhibited TGF-beta-mediated repression of RON promoter activity. These studies indicate that loss of Smad4 contributes to aberrant RON expression and that cross-talk of Smad4-independent TGF-beta signaling and the RON pathway promotes an invasive phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310076      PMCID: PMC2431051          DOI: 10.1074/jbc.M800154200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2.

Authors:  Mansoor M Ahmed; Rachael A Alcock; Damodaran Chendil; Swatee Dey; Anindita Das; Kolaparthi Venkatasubbarao; Mohammed Mohiuddin; LuZhe Sun; William E Strodel; James W Freeman
Journal:  J Biol Chem       Date:  2001-11-01       Impact factor: 5.157

Review 2.  Signal transduction by the TGF-beta superfamily.

Authors:  Liliana Attisano; Jeffrey L Wrana
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

3.  TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses.

Authors:  Li Yu; Mindy C Hébert; Ying E Zhang
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

Review 4.  Growth factors and their receptors in pancreatic cancer.

Authors:  F Ozawa; H Friess; A Tempia-Caliera; J Kleeff; M W Büchler
Journal:  Teratog Carcinog Mutagen       Date:  2001

5.  Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1.

Authors:  K D Fralix; M M Ahmed; C Mattingly; C Swiderski; P C McGrath; K Venkatasubbarao; N Kamada; M Mohiuddin; W E Strodel; J W Freeman
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

Review 6.  Pancreatic cancer biology and genetics.

Authors:  Nabeel Bardeesy; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

7.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.

Authors:  R E Wilentz; C A Iacobuzio-Donahue; P Argani; D M McCarthy; J L Parsons; C J Yeo; S E Kern; R H Hruban
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

Review 8.  The ErbB receptors and their role in cancer progression.

Authors:  Thomas Holbro; Gianluca Civenni; Nancy E Hynes
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

9.  The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.

Authors:  Martine Deckers; Maarten van Dinther; Jeroen Buijs; Ivo Que; Clemens Löwik; Gabri van der Pluijm; Peter ten Dijke
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

10.  Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.

Authors:  Yong-Qing Zhou; Chao He; Yi-Qing Chen; Dong Wang; Ming-Hai Wang
Journal:  Oncogene       Date:  2003-01-16       Impact factor: 9.867

View more
  33 in total

Review 1.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells.

Authors:  Shujie Zhao; Yubao Wang; Lin Cao; Michel M Ouellette; James W Freeman
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

Review 3.  Deploying mouse models of pancreatic cancer for chemoprevention studies.

Authors:  Paul J Grippo; David A Tuveson
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-02

4.  Effects of PTCs on nonsense-mediated mRNA decay are dependent on PTC location.

Authors:  Heegyum Moon; Xuexiu Zheng; Tiing Jen Loh; Ha Na Jang; Yongchao Liu; Da-Woon Jung; Darren R Williams; Haihong Shen
Journal:  Oncol Lett       Date:  2017-01-19       Impact factor: 2.967

5.  Automatic cell fusion via optically-induced dielectrophoresis and optically-induced locally-enhanced electric field on a microfluidic chip.

Authors:  Yu-Chun Hsiao; Chih-Hung Wang; Wen-Bin Lee; Gwo-Bin Lee
Journal:  Biomicrofluidics       Date:  2018-05-22       Impact factor: 2.800

Review 6.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

7.  Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.

Authors:  Gang Zhao; Hong Zhao; Ling Tu; Xizhen Xu; Changlong Zheng; Meihua Jiang; Peihua Wang; Daowen Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-02-14

8.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

Review 9.  SMAD4 and its role in pancreatic cancer.

Authors:  Xiang Xia; Weidong Wu; Chen Huang; Gang Cen; Tao Jiang; Jun Cao; Kejian Huang; Zhengjun Qiu
Journal:  Tumour Biol       Date:  2014-12-03

10.  Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling.

Authors:  Paul T Fullerton; Chad J Creighton; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.